Gan & Lee Pharmaceuticals Management

Management criteria checks 4/4

Gan & Lee Pharmaceuticals' CEO is Kai Du, appointed in Jul 2020, has a tenure of 4.42 years. directly owns 0.087% of the company’s shares, worth CN¥23.42M. The average tenure of the management team and the board of directors is 4.4 years and 4.7 years respectively.

Key information

Kai Du

Chief executive officer

CN¥1.0m

Total compensation

CEO salary percentage	n/a
CEO tenure	4.4yrs
CEO ownership	0.09%
Management average tenure	4.4yrs
Board average tenure	4.7yrs

Recent management updates

Recent updates

CEO

Kai Du (47 yo)

4.4yrs

Tenure

CN¥1,041,900

Compensation

Mr. Kai Du is General Manager of Gan & Lee Pharmaceuticals. since July 20, 2020 and has been its Director since April 26, 2019.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Gan Zhongru	Founder & Chairman	26.9yrs	CN¥457.20k	35.48% CN¥ 9.5b
Kai Du	GM & Director	4.4yrs	CN¥1.04m	0.087% CN¥ 23.4m
Cheng Sun	CFO & Deputy GM	4.4yrs	CN¥695.20k	0.089% CN¥ 23.9m
Wei Chen	Deputy GM & Director	less than a year	CN¥892.20k	0.087% CN¥ 23.4m
Weiqiang Song	Deputy GM & Director	8.9yrs	CN¥960.50k	0.087% CN¥ 23.4m
Rong Zou	Secretary	7yrs	CN¥695.00k	0.087% CN¥ 23.4m
Cheng Xing	Deputy General Manager	4.4yrs	CN¥752.80k	0.087% CN¥ 23.4m
Zifei Yuan	Deputy General Manager	4.4yrs	CN¥710.50k	0.087% CN¥ 23.4m
Zhi Li	Deputy General Manager	less than a year	no data	no data

4.4yrs

Average Tenure

42yo

Average Age

Experienced Management: 603087's management team is considered experienced (4.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Gan Zhongru	Founder & Chairman	26.9yrs	CN¥457.20k	35.48% CN¥ 9.5b
Kai Du	GM & Director	5.7yrs	CN¥1.04m	0.087% CN¥ 23.4m
Wei Chen	Deputy GM & Director	3.3yrs	CN¥892.20k	0.087% CN¥ 23.4m
Weiqiang Song	Deputy GM & Director	9.3yrs	CN¥960.50k	0.087% CN¥ 23.4m
Jiao Jiao	Director	3.8yrs	CN¥1.04m	0.045% CN¥ 12.2m
Lei Yin	Director	3.8yrs	CN¥897.10k	0.020% CN¥ 5.4m
Yanqing He	Independent Director	5.7yrs	CN¥72.00k	no data
Guojun Zheng	Independent Director	5.7yrs	CN¥72.00k	no data
Yi Wang	Supervisor	3.8yrs	no data	no data
Tao Zhang	Chairman of the Board of Supervisors	3.3yrs	no data	no data
Jiaxin Wang	Supervisor	5.7yrs	no data	no data
Zengyi Chang	Independent Director	2.6yrs	CN¥72.00k	no data

4.7yrs

Average Tenure

44.5yo

Average Age

Experienced Board: 603087's board of directors are considered experienced (4.7 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/24 06:07
End of Day Share Price	2024/12/24 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Gan & Lee Pharmaceuticals. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Zhu Chen	Citic Securities Co., Ltd.
Shitong Han	Citic Securities Co., Ltd.
Tianyi Yan	Goldman Sachs

Gan & Lee Pharmaceuticals Management

Management criteria checks 4/4

Key information

Recent management updates

Gan & Lee Pharmaceuticals., Annual General Meeting, May 16, 2024

Less than half of directors are independent

Recent updates

Gan & Lee Pharmaceuticals.(SHSE:603087) dropped from SSE 180 Index

Gan & Lee Pharmaceuticals Announces Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks

Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults

Third quarter 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.23 in 3Q 2023)

Gan & Lee Pharmaceuticals. to Report Q3, 2024 Results on Oct 23, 2024

Investor sentiment improves as stock rises 18%

Gan & Lee Pharmaceuticals. (SHSE:603087) announces an Equity Buyback for CNY 300 million worth of its shares.

Second quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.15 in 2Q 2023)

Gan & Lee Pharmaceuticals. to Report First Half, 2024 Results on Aug 29, 2024

Gan & Lee Pharmaceuticals., Annual General Meeting, May 16, 2024

First quarter 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.09 in 1Q 2023)

Gan & Lee Pharmaceuticals. to Report Q1, 2024 Results on Apr 25, 2024

Gan & Lee Pharmaceuticals. to Report Fiscal Year 2023 Results on Apr 25, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: CN¥0.23 (vs CN¥0.39 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.55 loss in 2Q 2022)

First quarter 2023 earnings released: EPS: CN¥0.09 (vs CN¥0.20 in 1Q 2022)

Gan & Lee Pharmaceuticals.(XSSC:603087) dropped from FTSE All-World Index (USD)

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.39 loss per share (vs CN¥0.90 profit in 3Q 2021)

Gan & Lee Pharmaceuticals. announced that it expects to receive CNY 813.6 million in funding

Second quarter 2022 earnings released: CN¥0.55 loss per share (vs CN¥0.32 profit in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.34 in 1Q 2021)

Gan & Lee Pharmaceuticals Co., Ltd. Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for a Novel Glucagon-Like Peptide-1 Analogue, GZR18

Third quarter 2021 earnings released: EPS CN¥0.90 (vs CN¥0.70 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.34 in 2Q 2020)

Gan & Lee Pharmaceuticals Co., Ltd. Announces Positive Phase 1 Clinical Trial Results at the 81st Scientific Sessions of the American Diabetes Association

First quarter 2021 earnings released: EPS CN¥0.34 (vs CN¥0.24 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥2.31 (vs CN¥2.31 in FY 2019)

New 90-day low: CN¥121

FDA Grants Fast Track Designation for Gan & Lee Pharmaceuticals Co., Ltd.'s GLR2007, for the Treatment of Patients with Glioblastoma

Investor sentiment improved over the past week

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources